Pelgifatamab

Synonyms: 柯立派妥单抗; BAY-2315497; PSMA-TTC
Peligifatamab 是一种靶向 PSMA 的 α 放射性免疫偶联物,对人源靶点的 EC50 为 1.2 nM,可在 PSMA 阳性前列腺癌细胞中诱导 DNA 损伤、DNA 双链断裂、细胞周期阻滞及细胞凋亡 (Apoptosis),并以依赖细胞 PSMA 表达水平的方式降低细胞活力,同时在前列腺癌骨转移模型中抑制肿瘤生长及肿瘤诱导的异常骨生长,在皮下前列腺癌模型及异种移植模型中表现出抗肿瘤效力,可用于转移性去势抵抗性前列腺癌的研究。
产品编号: MS-F29219 纯度: 99.884% CAS No.: 2414550-93-7
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Peligifatamab 是一种靶向 PSMA 的 α 放射性免疫偶联物,对人源靶点的 EC50 为 1.2 nM,可在 PSMA 阳性前列腺癌细胞中诱导 DNA 损伤、DNA 双链断裂、细胞周期阻滞及细胞凋亡 (Apoptosis),并以依赖细胞 PSMA 表达水平的方式降低细胞活力,同时在前列腺癌骨转移模型中抑制肿瘤生长及肿瘤诱导的异常骨生长,在皮下前列腺癌模型及异种移植模型中表现出抗肿瘤效力,可用于转移性去势抵抗性前列腺癌的研究。

生物实验数据

生物活性 Peligifatamab is a PSMA-targeted alpha radioimmunoconjugate with an EC50 of 1.2 nM against the human target that induces DNA damage, DNA double-strand breaks, cell cycle arrest, and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells, reduces cell viability in a manner dependent on cellular PSMA expression levels, inhibits tumor growth and tumor-induced abnormal bone growth in a bone metastasis model of prostate cancer, exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models, and can be used for research on metastatic castration-resistant prostate cancer.
IC50 & Target

FOLH1/PSMA

体内研究
(In Vivo)

Peligifatamab (75-500 kBq/kg; i.v.; single dose; weekly; biweekly) 在 LNCaP 皮下移植瘤模型中诱导抗肿瘤效力。
Peligifatamab (100-500 kBq/kg; i.v.; single dose) 在雄激素非依赖性和去势抵抗性皮下前列腺癌异种移植物中表现出强效抗肿瘤功效,在 MDA-PCa-2b 异种移植物中单次给药 500 kBq/kg 时,T/C 比值可低至 0.09。
Peligifatamab (75-500 kBq/kg; 4×75 kBq/kg; 4×125 kBq/kg; 2×150 kBq/kg; 2×250 kBq/kg; i.v.; single dose; weekly; biweekly) 可在前列腺癌异种移植物中诱导强烈的抗肿瘤效力,其中在 ST1273 异种移植物中单次给予 500 kBq/kg 剂量时,T/C 比值可低至 0.01。
Peligifatamab (100-200 kBq/kg; i.v.; single dose) 可在胫骨内前列腺癌骨转移模型中强效抑制肿瘤生长及肿瘤诱导的骨组织改变,单次 100 kBq/kg 剂量即可使 T/C 比值达到 0.03。
Peligifatamab (500 kBq/kg; 0.14-5 mg/kg total antibody; i.v.; single dose) 在 22Rv1 异种移植模型中,当总抗体剂量为 0.14 至 1.5 mg/kg 时可保持强大的抗肿瘤功效,而当总抗体剂量为 5 mg/kg 时功效会下降。

Animal Model: CB17-Scid (male)
Dosage: 75 kBq/kg; 150 kBq/kg; 300 kBq/kg; 4 × 75 kBq/kg; 2 × 150 kBq
Administration: i.v.; single dose; weekly for 4 doses; biweekly for 2 doses
Result: Achieved T/C ratios of 0.51, 0.42, and 0.31 with single doses of 75, 150, and 300 kBq/kg, respectively.
Resulted in 7 of 10 mice showing partial response or stable disease with 300 kBq/kg single dose.
Achieved T/C ratios of 0.07 and 0.12 with fractionated doses of 4 × 75 kBq/kg and 2 × 150 kBq/kg, respectively.
Animal Model: athymic nude (male); NMRI Nude (male)
Dosage: 100 kBq/kg (0.14 mg/kg total antibody); 250 kBq/kg (0.14 mg/kg total antibody); 500 kBq/kg (0.14 mg/kg total antibody)
Administration: i.v.; single dose
Result: Achieved T/C ratios of 0.33, 0.18, and 0.09 with single doses of 100, 250, and 500 kBq/kg in MDA-PCa-2b xenografts, respectively.
Achieved T/C ratios of 0.54, 0.37, and 0.19 with single doses of 100, 250, and 500 kBq/kg in 22Rv1 xenografts, respectively.
Achieved T/C ratios of 0.27, 0.47, and 0.15 with single doses of 100, 250, and 500 kBq/kg in C4-2 xenografts, respectively.
Induced statistically significant tumor growth inhibition at ≥250 kBq/kg in MDA-PCa-2b and 22Rv1 models, and starting at 100 kBq/kg in the C4-2 model.
Animal Model: NMRI nude (female); CB17-Scid (male)
Dosage: 125 kBq/kg (0.14 mg/kg total antibody); 250 kBq/kg (0.14 mg/kg total antibody); 500 kBq/kg (0.14 mg/kg total antibody); 4 × 125 kBq/kg (0.14 mg/kg total antibody per dose); 2 × 250 kBq/kg (0.14 mg/kg total antibody per dose); 75 kBq/kg (0.14 mg/kg total antibody); 150 kBq/kg (0.14 mg/kg total antibody); 300 kBq/kg (0.14 mg/kg total antibody); 4 × 75 kBq/kg (0.14 mg/kg total antibody per dose); 2 × 150 kBq/kg (0.14 mg/kg total antibody per dose)
Administration: i.v.; single dose; weekly for 4 doses; biweekly for 2 doses
Result: Achieved T/C ratios of 0.3, 0.05, and 0.01 with single doses of 125, 250, and 500 kBq/kg in ST1273 xenografts, respectively.
Resulted in 5 partial responses and 4 complete responses out of 10 mice with 500 kBq/kg single dose in ST1273 xenografts.
Reduced serum PSA levels effectively with 250 and 500 kBq/kg single doses in ST1273 xenografts.
Achieved T/C ratios of 0.13 and 0.04 with fractionated doses of 4 × 125 kBq/kg and 2 × 250 kBq/kg in ST1273 xenografts, respectively.
Achieved T/C ratios of 0.39, 0.28, and 0.07 with single doses of 75, 150, and 300 kBq/kg in KUCaP-1 xenografts, respectively.
Resulted in 2 stable disease and 6 partial responses out of 10 mice with 300 kBq/kg single dose in KUCaP-1 xenografts.
Achieved T/C ratios of 0.24 and 0.25 with fractionated doses of 4 × 75 kBq/kg and 2 × 150 kBq/kg in KUCaP-1 xenografts, respectively.
Achieved T/C ratios of 0.58 and 0.27 with single doses of 150 and 300 kBq/kg in LuCaP 86.2 xenografts, respectively.
Resulted in 5 stable disease, 1 partial response, and 1 complete response out of 10 mice with 300 kBq/kg single dose in LuCaP 86.2 xenografts.
Animal Model: NOD.scid (male)
Dosage: 100 kBq/kg (0.14 mg/kg total antibody); 200 kBq/kg (0.14 mg/kg total antibody)
Administration: i.v.; single dose
Result: Reduced LNCaP-luc tumor burden in bone with T/C ratios of 0.03 and 0.14 based on bioluminescence with single doses of 100 and 200 kBq/kg, respectively.
Lowered serum PSA levels with single doses of 100 and 200 kBq/kg.
Significantly inhibited the total area of tumor-induced bone changes compared to vehicle controls with single doses of 100 and 200 kBq/kg.
Animal Model: NMRI Nude (male)
Dosage: 500 kBq/kg (0.14 mg/kg total antibody); 500 kBq/kg (0.75 mg/kg total antibody); 500 kBq/kg (1.5 mg/kg total antibody); 500 kBq/kg (5 mg/kg total antibody)
Administration: i.v.; single dose
Result: Achieved T/C ratios of 0.13-0.31 with single 500 kBq/kg doses at total antibody doses of 0.14, 0.75, and 1.5 mg/kg.
Resulted in reduced efficacy with a T/C ratio of 0.84 with single 500 kBq/kg dose at 5 mg/kg total antibody dose.
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 2414550-93-7
别名 柯立派妥单抗; BAY-2315497; PSMA-TTC

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础